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Abstract 
Background: Tobacco smoking, driven by the addictive properties of nicotine, is the 
most prevalent preventable cause of death in the Western World. Accumulated evidence 
suggests that nicotine may increase appetitive responding for non-drug incentives in the 
environment. Methods: To test this hypothesis, we conducted a randomized, double-
blind, placebo-controlled, crossover study of the effect of a single dose of transdermal 
nicotine on reward responsiveness in 30 psychiatrically healthy non-smokers. A novel 
signal detection task in which correct responses were differentially rewarded in a 3:1 
ratio was used to assess the extent to which participants modulated their behavior as a 
function of reward. Results: Despite expected adverse effects such as nausea, nicotine 
significantly increased response bias toward the more frequently rewarded condition, at 
the expense of accuracy, independent of effects on attention or overall vigilance. 
Additionally, response bias on placebo was greater in participants who received nicotine 
in the first session, indicating that an effect of nicotine on reward responsiveness or 
reward-based learning persisted for at least one week. Conclusions: These findings 
suggest that a single dose of nicotine enhances response to non-drug-related rewards in 
the environment, with lasting effects. This effect may contribute to reinforcement of early 
smoking behavior and development of nicotine dependence. 
 
 
Clinical Trials Registry:ClinicalTrials.gov 
URL:  http://ClinicalTrials.gov/ 
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Introduction 
Unlike substances such as cocaine and heroin, euphoric effects of nicotine are mild. 
Despite this, nicotine is highly addictive [1]. Animal studies indicate that reinforcing 
properties of nicotine may be mediated through enhancement of salience of non-drug-
related experiences; nicotine self-administration is associated with increased 
responsiveness to non-drug reward [2], while nicotine withdrawal is associated with 
refractoriness to reward [3]. Phasic dopamine release modulates salience attribution and 
motivation [4, 5], and nicotine may increase appetitive responding for non-drug 
incentives via activation of presynaptic nicotinic receptors (nAChR’s) on 
mesocorticolimbic dopaminergic neurons [1, 2]. Consistent with this hypothesis, nicotine 
enhances the incentive value of monetary reward in smokers following overnight 
abstinence [6]. Whether nicotine enhances responding for non-drug incentives in the 
absence of potentially confounding effects of nicotine withdrawal or chronic effects of 
nicotine on reward responsiveness is unknown.  We conducted a randomized, double-
blind, placebo-controlled crossover study of a single dose of transdermal nicotine in 
healthy adult non-smokers to determine if responsiveness to non-drug reward is increased 
in non-smokers acutely treated with nicotine. This was an ancillary study conducted in 
conjunction with a larger study of the effect of nicotine on cognitive performance in non-
smokers [7]. 
     Ruth S. Barr  
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Methods 
The study took place at an urban community mental health clinic (Freedom Trail Clinic) 
and was approved by Institutional Review Boards of the Massachusetts General Hospital 
and the Massachusetts Department of Mental Health. All participants were assessed by a 
doctoral level investigator as competent to consent and provided written informed 
consent.  
 
Participants: 
Adults, aged 18-60, were recruited via local press advertisement and were eligible to 
participate if they were non-smokers for ≥3 months with salivary cotinine < 10 ng/ml 
(Nicalert
TM, JANT Pharmacal Corp., Encino, CA) and expired air carbon monoxide (CO) 
<9 ppm (Micro Smokerlyzer III, Bedfont Scientific Ltd., Kent, U.K.). Participants were 
excluded if they reported a lifetime history of Axis I psychiatric diagnosis by Structured 
Clinical Interview for DSM-IV, head injury, first-degree relative with a schizophrenia 
spectrum disorder, recent exposure to investigational medications, or saliva positive for 
drugs or alcohol (Accutest Saliva Test
TM, JANT Pharmacal Corp., Encino, CA, ALCO 
Screen, CHEMATICS, Inc., North Webster, IN). Participants completed the Beck 
Depression Inventory (BDI) at baseline and were randomized by computer-generated, 
random number assignment with concealed allocation for order of receiving active or 
placebo patches. The randomization procedure was conducted by a staff member from 
another research team, was concealed using opaque envelopes and all study investigators, 
staff and subjects were blind to group allocation for the duration of the study. Participants 
then attended two study visits, separated by 1-2 weeks, at which they wore two 7 mg      Ruth S. Barr  
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(Nicoderm CQ) nicotine or identical placebo patches (Alza Corp., Mountain View, CA). 
We elected to use two 7 mg patches instead of a single 14 mg patch to allow for dose 
reduction if participants experienced adverse effects. Following application of patches, 
participants had lunch and watched an affectively neutral or slightly positive movie of 
their choice.  Tests of reward responsiveness were performed after three hours. At the end 
of the testing period, blood was drawn for serum nicotine concentration and patches were 
removed. 
 
Tasks and Procedures: 
A signal detection task, designed to measure shift in responding toward a differentially 
(more) rewarded stimulus, was administered twice, in two separate sessions, 3 hours after 
nicotine patch and after placebo patch application, as an objective measure of reward 
responsiveness [8-10]. This operationalization of response bias as a measure of reward 
responsiveness fits with the view that reinforcers are stimuli that increase frequency of 
responding [11]. For each trial, participants were asked to choose which of two stimuli 
(short or long mouth) was presented on a previously mouthless cartoon face by making a 
corresponding response on a keyboard. At each session, participants performed three 
blocks, each containing 50 trials of the short and 50 trials of the long mouth. Critically, 
the difference between mouth sizes (11.5 mm vs. 13 mm) and the stimulus exposure time 
(100 ms) is small, making the participants’ choice difficult, and thus allowing the 
development of a response bias. In line with prior studies [10], an asymmetric reinforcer 
ratio was used to elicit a response bias. Correct identification of one stimulus was 
rewarded (“Correct!! You won 5 Cents”) three times more frequently (“rich stimulus”)     Ruth S. Barr  
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compared to correct identification of the other stimulus (“lean stimulus”). To expose each 
subject to the intended 3:1 reward ratio, only 40 correct trials (30 rich, 10 lean) were 
rewarded in each block. Choice of rich stimuli (long vs. short mouth) was 
counterbalanced between participants and across visits (e.g. if the long mouth was the 
rich stimulus at the first visit then the short mouth would be the rich stimulus at the 
second). Before the task, participants were instructed to try to win as much money as 
possible and that the money they win will be given to them to keep. They were 
specifically instructed that not all correct responses would receive a reward feedback, and 
that lack of feedback did not indicate inaccuracy and that they receive no feedback for 
errors. They were not informed, however, about the differential reward schedule. Prior 
studies with this paradigm in healthy subjects have shown that unequal frequency of 
reward to correct responses to the more frequently (rich) vs. less frequently rewarded 
(lean) stimulus produces a systematic preference for the response paired with the more 
frequent reward, which typically increases across blocks [8, 12, 13].  Performance is 
analyzed in terms of response bias, an index of the tendency to choose the more rewarded 
stimulus and an objective assessment of reward responsiveness. Control analyses are 
performed for accuracy, discriminability, and reaction time (RT), which provide 
information about overall task performance. Response bias (log b) and discriminability 
(log d) were computed as follows [10]: 
⎟ ⎟
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⎝
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As evident from the formula, a high response bias is observed if a participant has a high 
number of correct identifications for the more frequently rewarded (rich) stimulus and a 
low number of correct identifications for the lean stimulus. Discriminability, which     Ruth S. Barr  
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assessed participants’ ability to distinguish between the two stimuli, was used as an 
indicator of task difficulty. Participants also completed the State Trait Anxiety Inventory 
(state form) and other cognitive tests reported separately [7] .  
 
Data Reduction and Analyses: 
Trials with RT <150 ms or >2500 ms and/or >3 standard deviations from the mean 
computed for each subject individually after applying a logarithmic transformation were 
identified as outlier responses and excluded. There were a priori criteria to exclude 
participants with accuracy of less than chance (50%) or total rewards of <30 in any block. 
Data from two participants were removed by these criteria. Data were assessed for 
distributional properties prior to analysis and one variable (RT) required log 
transformation to meet criteria for normal distribution (pre-transformation skew=1.71 + 
0.31, kurtosis = 3.70 +0.61; post-transformation skew= 0.97+0.31, kurtosis=1.27 +0.61). 
Identical split-plot repeated measures analyses of variance (ANOVA) were performed for 
response bias and discriminability with Treatment (nicotine, placebo) and Block (1, 2 and 
3) included as within-subject factors, and Order of Drug Administration as the between-
subject factor. For analyses of RT and accuracy, Stimulus Type (lean vs. rich) was 
included as an additional within-subject factor. In case of significant ANOVA effects, 
posthoc Newman-Keuls tests were performed. Greenhouse-Geisser corrections were 
employed when Mauchley’s test of sphericity was significant. Data are presented as mean 
+ standard deviation. Analyses were performed using SPSS for Windows 10 (SPSS Inc.) 
and Statistica. 
     Ruth S. Barr  
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Results 
All study procedures took place between January 2005 and July 2006. Thirty-two 
participants completed all study procedures (i.e., a placebo and nicotine session). Data for 
two participants were lost (they met a priori criteria for exclusion). Data from 30 
participants are presented. See Supplementary Material 1. Demographic characteristics 
are given in Table 1. Serum nicotine levels were higher in the nicotine condition (7.5 vs 
<0.5 ng/ml, t=12.6, p<0.0001). 
 
Response Bias:  
As shown in Figure 1, nicotine increased responding to reward (main effect F1,28=8.18, 
p=0.008). Interestingly, while there was no overall interaction between Treatment 
(between session factor) and Block (within session factor) (F1.5, 43.0=0.95, p=0.37), there 
was a Treatment by Block by Order of Treatment Administration interaction (F1.5, 
43=4.29, p=0.029). Follow-up ANOVAs, considering each visit separately, revealed a 
main effect of Treatment in each visit (first visit: F1, 28=4.31, p=0.047; second visit: F1, 
28=4.76, p=0.038), confirming that participants (n = 15) had significantly greater response 
bias when receiving nicotine than when receiving placebo (n = 15) at both visits. See 
Figure 2. To further evaluate the triple interaction, Block by Order of Treatment 
Administration ANOVAs were run for response bias in nicotine and placebo conditions 
separately. Importantly, a Block by Order effect emerged for response bias on placebo 
(F1.61, 45.14=5.20, p=0.014), but not nicotine (F1.36, 38.19=0.62, p=0.48). This interaction was 
due to development of greater response bias across the three blocks in the placebo 
condition for participants who received nicotine first compared with those who received     Ruth S. Barr  
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placebo first (RB3-RB1= 0.16±0.19 vs. -0.10±0.14; t38=4.30, p=0.0002).  
 
Because of lasting effects of nicotine on response bias observed in this study and reports 
of persistent effects of chronic nicotine use on cognitive function [14], analyses were 
repeated in a subsample of 23 participants who reported never smoking a single cigarette. 
The effect of nicotine on response bias was unchanged; the main effect of Treatment 
remained significant (F1,21=13.79, p=0.001).    
 
Control Analyses: 
Accuracy:  
The Treatment (placebo, nicotine) by Block (1, 2 and 3) by Order of Drug Administration 
by Stimulus Type (lean, rich) ANOVA on accuracy scores indicated that the main effect 
of Treatment was not significant (F1,28 =0.0005, p= 0.98). Replicating prior studies with 
independent samples[8, 13], accuracy was significantly greater for the more rewarded 
stimulus type (Stimulus Type: F1,28=36.07, p=<0.0001), an effect that was seen in all three 
blocks (Newman-Keuls, ps < 0.001). In addition, a significant Stimulus Type by Block 
interaction (F 2,56=3.66, p=0.032) was due to lower lean accuracy in Blocks 2 (Newman-
Keuls, p = 0.050) and 3 (Newman-Keuls, p < 0.060) vs Block 1. Overall, these findings 
indicate that the differential reinforcement schedule successfully elicited a behavioral 
preference toward the more frequently rewarded (rich) stimulus. Importantly, this effect 
was greater on nicotine, (Treatment by Stimulus Type interaction F1,28=5.08, p=0.03), 
indicating that when participants were on nicotine, their accuracy was greater in the rich 
condition and lower in the lean condition than when they were on placebo. See Figure 3.      Ruth S. Barr  
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Discriminability: 
There was no main effect of Block on discriminability, indicating no change over the 
course of the test. There was a trend for an effect of nicotine on discriminability (log d’ 
nicotine = 0.98 + 0.34; log d’ placebo = 0.93 + 0.28) (main effect of Treatment: F1,28 
=3.12, p=0.09).  
 
Reaction Time: 
As expected, RT was faster for the rich stimulus (rich: 441.9 +103.2 ms vs. lean: 467.8 
+118.7 ms; main effect of Stimulus Type: F1,28=36.6, p=1.6E
-6) and in the nicotine 
condition (main effect of Treatment F1,28=4.75, p=0.04). See Figure 4. 
 
Adverse Events: 
State anxiety was higher in the nicotine condition (STAI=33.5+9.3 vs. 29.7+6.5, t =-2.5, 
p=0.02). Thirteen participants experienced nausea and 4 required dose reduction to 7 mg. 
Other adverse effects included skin irritation (n=12), dizziness (n=9), headache (n=8) and 
palpitations (n=1). No significant correlation emerged between number and severity of 
side effects and change in response bias between blocks 1 and 3. 
 
Discussion 
This is the first study to demonstrate that nicotine can enhance responding for a positive 
response cue and monetary reward in non-nicotine dependent as well as nicotine-naïve 
humans. These data suggest that nicotine increases salience of rewarding stimuli in the     Ruth S. Barr  
 
11 
 
environment, a property that may contribute to initial development and maintenance of 
nicotine dependence. Cigarette smoking takes place in the context of many daily 
activities, and nicotine may increase the salience of environmental reinforcers in these 
situations. If attempts at smoking cessation are associated with loss of salience of 
numerous everyday pleasurable experiences then this may make smoking abstinence 
more difficult to sustain, triggering relapse. 
 
Striatal dopamine and acetylcholine release are believed to play an important role in 
probabilistic reward-based learning and attention, signaling behavioral significance of 
environmental events and influencing decision making or choice [15-19]. The elimination 
of cholinergic neurons in the striatum results in impairments in reward- related learning 
[20], and phasic activation of both striatal dopaminergic and cholinergic neurons has 
been demonstrated in response to rewarding stimuli [16]. Data from animal models 
investigating the effects of d-amphetamine on responding for conditioned reinforcers [21-
23] support a role for phasic dopaminergic activation in enhancing response to reward- 
related stimuli. Based on these animal data, we postulate that effect of nicotine to 
enhance responding for positive response cues may be mediated via dopamine or 
acetylcholine-dependent mechanisms in mesocorticolimbic regions. Future studies will 
be required to test this hypothesis. 
 
Nicotine did not significantly modulate discriminability on the task, indicating that 
effects on response bias were not mediated by improvement in attention or general task 
performance. Furthermore, if the effect of nicotine on response bias described were     Ruth S. Barr  
 
12 
 
primarily due to improvement in attention and overall vigilance, we would expect 
improved accuracy for both types of stimuli presented in the task rather than 
differentially increased responding for the stimulus associated with the more frequent 
reward at the expense of accuracy for the lean stimulus, as observed. In addition, reaction 
time was faster on nicotine due to an expected improvement in motor speed. However, 
the signal detection task measures the tendency to choose the more rewarded response 
and is independent of speed.  
 
Importantly, a carryover effect of nicotine on reward responsiveness was observed. This 
is consistent with a finding in animals in which nicotine self-administration was 
associated with increased reward responsiveness during active use and for 36 days after 
removal of nicotine availability [2]. These results suggest that a single nicotine dose may 
have lasting effects on reward sensitivity in humans, potentially through its effects on 
incentive or motivational salience, which may contribute to repeated use and the 
development of dependence.  
 
The study was conducted in non-smokers to avoid confounding effects of nicotine use on 
reward responsiveness [2, 24]. Although the observed effect of nicotine on reward 
responsivity was small, it is possible that even a small enhancement in sensitivity to 
rewarding environmental stimuli may be sufficient to reinforce smoking behavior in 
vulnerable individuals. Additionally, nicotine delivered by smoke would have faster 
pharmacokinetics and may have a greater effect on responsivity to reward than that 
observed for transdermal nicotine. There are limitations to our study that require specific     Ruth S. Barr  
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mention. Participants had quite low levels of depressive symptoms as indicated by low 
BDI scores, limiting our ability to assess clinical correlates of response bias development.  
The findings of this study may however have relevance for those with disorders of 
hedonic tone such as anxiety, depressive disorders or schizophrenia who also have high 
rates of smoking [25-27]. These individuals may be particularly vulnerable to become 
nicotine dependent if they experience a reduction in anhedonia when they smoke. Future 
studies investigating generalizability of the present findings to those with disorders of 
hedonic tone are warranted.      Ruth S. Barr  
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Tables/Figure Legends 
 
Table 1. 
F= Female, M=Male, C=Caucasian, A=African American, Cigarettes per day calculated 
for former smokers, BDI=Beck Depression Inventory. The BDI anhedonia subscale 
includes: loss of pleasure, loss of interest, loss of energy and loss of interest in sex.[28] 
 
Figure 1. 
Title: Response Bias 
Nicotine treatment increased response bias in the signal detection task (main effect of 
Treatment: F1, 28=8.18, p=0.008) indicating increased responding for the more rewarded 
(rich) Stimulus Type. Data are presented as means + standard error. 
 
Figure 2. 
Title: Response Bias at Visit One and Visit Two 
Nicotine significantly increased response bias at both visits (main effect of Treatment at 
visit 1: F1, 28=4.31, p=0.047; visit 2: F1, 28=4.76, p=0.038). 
 
Figure 3. 
Title: Accuracy 
A main effect of Stimulus Type (F1,28=36.07, p=<0.0001) indicates greater accuracy for 
the more rewarded (rich) stimulus. A Treatment by Stimulus Type interaction (F1,28=5.08, 
p=0.03) indicated that, compared to placebo, nicotine was associated with greater 
accuracy for the rich stimulus but lower accuracy for the lean stimulus.      Ruth S. Barr  
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Figure 4. 
Title: Reaction Time 
A significant main effect of both Stimulus Type (F1,28=36.6, p=1.6E
-6) and
 Treatment 
(F1,28=4.75, p=0.04) indicated that RT was faster for the more rewarded (rich) stimulus 
and in the nicotine condition vs placebo. 
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